吉贝尔(688566) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥169,358,593.98, representing a 45.97% increase compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2022 was ¥37,145,036.54, reflecting an 80.32% increase year-over-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥37,124,049.42, showing a significant increase of 112.45% compared to the previous year[5] - Basic and diluted earnings per share for Q3 2022 were both ¥0.20, an increase of 81.82% from the same period last year[6] - Total operating revenue for the first three quarters of 2022 reached CNY 426,569,744.86, an increase of 16.3% compared to CNY 366,826,002.01 in the same period of 2021[22] - Net profit for the third quarter of 2022 was CNY 78,942,288.10, representing a 4.0% increase from CNY 75,820,535.26 in the same quarter of 2021[23] - Basic and diluted earnings per share for the third quarter of 2022 were both CNY 0.42, compared to CNY 0.41 in the same quarter of 2021[24] Research and Development - The total R&D investment for Q3 2022 was ¥12,648,235.91, which is an 85.05% increase year-over-year[6] - R&D investment accounted for 7.47% of operating revenue in Q3 2022, up by 1.58 percentage points compared to the previous year[6] - Research and development expenses for new drugs increased by 75.68% year-on-year, totaling RMB 41,833,870.00[15] - Research and development expenses for the first three quarters of 2022 totaled CNY 41,833,870.00, significantly higher than CNY 23,813,200.62 in the same period of 2021, indicating a focus on innovation[22] - The company is advancing the development of new drugs JJH201501 and JJH201601[15] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,883,772,433.02, a 3.58% increase from the end of the previous year[6] - Total assets as of September 30, 2022, amounted to RMB 1,883,772,433.02, compared to RMB 1,818,686,866.85 at the end of 2021[19] - Total liabilities as of the end of the third quarter of 2022 amounted to CNY 269,935,507.78, an increase from CNY 210,396,612.27 at the end of the previous year[21] - The equity attributable to shareholders at the end of Q3 2022 was ¥1,607,846,151.63, reflecting a slight increase of 0.37% from the previous year[6] - Total equity attributable to shareholders of the parent company was CNY 1,607,846,151.63, a slight increase from CNY 1,601,985,101.69 in the previous year[21] Cash Flow - The cash flow from operating activities for the year-to-date was ¥103,504,097.97, representing a 4.42% increase[6] - Net cash flow from operating activities was $103,504,097.97, an increase from $99,120,817.12 in the previous year, reflecting a growth of approximately 3.8%[26] - Cash inflow from investment activities totaled $1,117,618,312.08, down from $1,387,683,406.62, indicating a decrease of about 19.5% year-over-year[27] - Total cash and cash equivalents at the end of the period stood at $760,789,488.56, compared to $460,138,487.63 at the end of the same quarter last year, representing an increase of approximately 65.2%[27] - The net increase in cash and cash equivalents for the period was -$253,920,254.49, compared to -$826,895,200.08 in the same quarter last year, showing a significant improvement[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 8,038[13] - The largest shareholder, Zhenjiang Zhongtian Investment Consulting Co., Ltd., holds 54,400,000 shares, accounting for 29.10% of total shares[13] Legal and Other Matters - The company is currently involved in a legal dispute with Hubei Jiuzhoutong and has filed a counterclaim[16] - The company has implemented a stock incentive plan, granting 7.33 million restricted shares at a price of RMB 12.30 per share[15] - The company’s inventory increased to RMB 33,425,671.52 from RMB 31,825,596.70 year-on-year[19] - The company’s long-term equity investments decreased to RMB 52,045,854.00 from RMB 56,625,042.03[19] - The company reported a decrease in unallocated profits to CNY 301,650,497.89 from CNY 320,147,417.75 in the same period last year[21] - The company experienced a significant increase in other payables, which rose to CNY 76,132,821.76 from CNY 20,278,559.67 in the previous year[21]